Comorbidities and mortality rate in COVID‐19 patients with hematological malignancies: A systematic review and meta‐analysis

Naimi, Adel; Yashmi, Ilya; Jebeleh, Reza; Mofrad, Mohammad Imani; Abhar, Shakiba Azimian; Jannesar, Yasaman; Heidary, Mohsen; Pakzad, Reza

doi:10.1002/jcla.24387

Cited by 30 publications

(25 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data regarding COVID-19 infection in acute leukemia patients is scarce, mainly on the wild (alpha) variant. Data showed that patients with acute leukemia reported having an increased risk of morbidity and mortality [ 9 , 15 ]. Our reported cases showed that acute leukemia patients could present with mild illness and have severe disease with the Omicron variant, as seen in case 2.…”

Section: Discussionmentioning

confidence: 99%

“…The SARS-CoV-2 disease is frequently associated with an elevated white cell count in patients with chronic lymphocytic leukemia, and mortality is related to age [ 7 , 8 ]. Previous studies showed that acute leukemia with SARS-CoV-2 infection had increased mortality [ 9 ]. However, data about the impact of the Omicron variant of the SARS-CoV-2 virus on patients with acute leukemia is small.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Case Series of SARS-CoV-2 Omicron Variant in Patients With Acute Leukemia

Ali¹,

Alamin²,

Abu-Tineh³

et al. 2022

Cureus

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a respiratory viral illness caused by coronavirus 2 (SARS-CoV-2). The disease often presents with non-specific symptoms, including fever, and fatigue, usually associated with respiratory symptoms (eg., cough) and other systemic involvement. The primary strategy to prevent transmission and reduce the disease severity of the SARS-CoV-2 infection is through vaccination. However, the virus had shown significant changes and mutations that resulted in the emergence of different strains. Each strain varies in its virulence, disease severity, and the body's immune system response. Previous reports showed that the Omicron variant causes mild disease. Little is known about the effect of Omicron in patients with acute leukemia. We present three patients with acute leukemia who had an infection with the Omicron variant of the SARS-CoV-2 virus.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Case Series of SARS-CoV-2 Omicron Variant in Patients With Acute Leukemia

Ali¹,

Alamin²,

Abu-Tineh³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…The clinical characteristics for COVID-19 appear 1–14 days after infection, and most patients develop symptoms within 3–7 days [ 12 , 13 ]. Fever, cough, and dyspnea were the most common symptoms in patients with COVID-19 pneumonia [ 14 , 15 ], followed by the manifestation of lower respiratory tract infections [ 16 ]. By contrast, upper respiratory tract symptoms were less common in these patients, indicating that the cells targeted by the virus might be located in the lower airway [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluating the characteristics of patients with SARS-CoV-2 infection admitted during COVID-19 peaks: A single-center study

Mousavi¹,

Ebrahimi²,

Moghaddam³

et al. 2023

Vacunas

Self Cite

View full text Add to dashboard Cite

“…The world has been fighting coronavirus disease 2019 (COVID-19) illness for nearly 2 years ( Koupaei et al, 2022a ; Naimi et al, 2022 ). COVID-19 was induced by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), which emerged in Wuhan, China ( Koupaei et al, 2021 ; Mahdizade Ari et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19

et al. 2022

Self Cite

View full text Add to dashboard Cite

Two years after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in December 2019, the first infections were identified in Wuhan city of China. SARS-CoV-2 infection caused a global pandemic and accordingly, 5.41 million deaths worldwide. Hence, developing a safe and efficient vaccine for coronavirus disease 2019 (COVID-19) seems to be an urgent need. Attempts to produce efficient vaccines inexhaustibly are ongoing. At present time, according to the COVID-19 vaccine tracker and landscape provided by World Health Organization (WHO), there are 161 vaccine candidates in different clinical phases all over the world. In between, protein subunit vaccines are types of vaccines that contain a viral protein like spike protein or its segment as the antigen assumed to elicit humoral and cellular immunity and good protective effects. Previously, this technology of vaccine manufacturing was used in a recombinant influenza vaccine (RIV4). In the present work, we review protein subunit vaccines passing their phase 3 and 4 clinical trials, population participated in these trials, vaccines manufactures, vaccines efficiency and their side effects, and other features of these vaccines.

show abstract

Comorbidities and mortality rate in COVID‐19 patients with hematological malignancies: A systematic review and meta‐analysis

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 30 publications

References 82 publications

A Case Series of SARS-CoV-2 Omicron Variant in Patients With Acute Leukemia

A Case Series of SARS-CoV-2 Omicron Variant in Patients With Acute Leukemia

Evaluating the characteristics of patients with SARS-CoV-2 infection admitted during COVID-19 peaks: A single-center study

A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19

Contact Info

Product

Resources

About